Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage
NCT01179529
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
OTHER
Sponsor class
Conditions
Atopic Dermatitis
Atopic Eczema
Interventions
DRUG:
Omalizumab (Xolair®)
Sponsor
Technical University of Munich